Terminated PHASE2 INTERVENTIONAL 1-arm NCT01604941

Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

Sponsor: Shire

Conditions Iron Overload Due to Repeated Red Blood Cell Transfusions

Interventions SPD602

Updated 11 times since 2017 Last updated: Jun 11, 2021 Started: Sep 14, 2012 Primary completion: Apr 18, 2014 Completion: Apr 18, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.

Other terminated trials from Shire

See all terminations from Shire

Other Iron Overload Due to Repeated Red Blood Cell Transfusions trials with similar outcome

NCT01671111 · Phase PHASE2 · Apr 2014

Browse all Iron Overload Due to Repeated Red Blood Cell Transfusions trials

A PHASE2 clinical study on Iron Overload Due to Repeated Red Blood Cell Transfusions, this trial is terminated or withdrawn. The trial is conducted by Shire and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Sep 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jan 2021 — Sep 2021 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beirut, Lebanon , Cagliari, Italy , Cairo, Egypt , Chicago, United States , Genova, Italy , Los Angeles, United States , Milan, Italy , New York, United States , Orbassano, Italy , Philadelphia, United States and 1 more location